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ABSTRACT
Purpose To assess accumulation and lysosomal sequestration
of 9 drugs used in respiratory indications (plus imipramine as
positive control) in the alveolar macrophage (AM) cell line
NR8383.
Methods For all drugs, uptake at 5 μMwas investigated at 37
and 4°C to delineate active uptake and passive diffusion pro-
cesses. Accumulation of basic clarithromycin, formoterol and
imipramine was also assessed over 0.1–100 μM concentration
range. Lysosomal sequestration was investigated using ammo-
nium chloride (NH4Cl), monensin and nigericin. Impact of
lysosomal sequestration on clarithromycin accumulation ki-
netics was investigated.
Results Both cell-to-medium concentration ratio (Kp) and up-
take clearance (CLuptake) ranged>400-fold for the drugs in-
vestigated. The greatest Kp was observed for imipramine
(391) and clarithromycin (82), in contrast to no accumulation
seen for terbutaline. A concentration-dependent accumula-
tion was evident for the basic drugs investigated. Imipramine
and clarithromycin Kp and CLuptake were reduced by 59–
85% in the presence of NH4Cl and monensin/nigericin, indi-
cating lysosomal accumulation, whereas lysosomal sequestra-
tion was not pronounced for the other 8 respiratory drugs.
Clarithromycin uptake rate was altered by NH4Cl,
highlighting the impact of subcellular distribution on accumu-
lation kinetics.
Conclusions This study provides novel evidence of the utility
of NR8383 for investigating accumulation and lysosomal se-
questration of respiratory drugs in AMs.
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Understanding drug disposition in the lungs remains a chal-
lenging task in the development of new medications for asth-
ma, chronic obstructive pulmonary disease and bacterial in-
fections (1). Several factors may affect the therapeutic efficacy
of inhaled drugs including delivery devices, formulation and
dose, drug physicochemical properties, metabolism and lung
clearance mechanisms and disease state (2–4). Phagocytic al-
veolar macrophages (AMs) represent important components
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of clearancemechanism of drugs from the respiratory airways.
While accumulation of certain drugs in AMs is required for
their therapeutic effect (e.g., macrolide antibiotics), this process
could affect the efficacy and duration of drugs targeting sub-
mucosa l compartments such as β2 -agoni s t s and
antimuscarinics. In addition, pronounced accumulation of ba-
sic drugs (often cationic amphiphilic drugs, i.e., CADs) in lyso-
somes of AMs may lead to drug induced phospholipidosis and
the presence of foamy macrophages in the airways (5).
Lysosomal sequestration of CADs has been attributed to the
pH differences between cytosol (pH=7.2) and lysosomes, as
the most acidic cell organelles (pH=4.7–4.8) (6). The
unionised form of basic drugs can rapidly diffuse into lyso-
somes where they become predominantly ionised and
‘trapped’ as a result of the limited permeability of lysosomal
membrane to ionised drugs. Lysosomal sequestration may
lead to significantly higher intracellular drug concentrations
which may have important therapeutic or toxicological con-
sequences (7,8). In addition, drug-drug interactions involving
lysosomotropic drugs have been proposed as an important
implication of lysosomal drug sequestration (8,9). In vitro
methods employed to investigate lysosomal sequestration in-
clude both direct approaches such as measuring drug concen-
trations in isolated lysosomes following homogenisation
(10–12) and indirect methods based on the use of chemical
agents to abolish lysosome-cytosol pH gradient (e.g., ammoni-
um chloride (NH4Cl), monensin and nigericin) (12–14).
Reduction in drug accumulation in the presence of these indi-
rect agents relative to control provides the extent of lysosomal
accumulation (reference studies provided in the Supplementary
Material, Table S1). In addition, assays involving the use of
lysosome specific fluorescent dye, LysoTrackerRed (LTR), have
also been reported for semiquantitative investigation of lysosom-
al drug sequestration (14–16).
NR8383 is an AM cell line originally derived by broncho-
alveolar lavage procedure of an adult male Sprague-Dawley
rat; this cell line was shown to exhibit several characteristics
and functions of freshly isolated rat AMs (17,18). Previous
uptake studies in NR8383 focused on a single drug per study
and mainly on antibiotics used for respiratory infections
(19,20). To date, there are no studies investigating the accu-
mulation in AMs of a substantial number of respiratory drugs
targeting other disease areas including asthma and chronic
obstructive pulmonary disease.
The aim of this study was to systematically assess the extent
of intracellular accumulation in AMs and the contribution of
lysosomal sequestration for nine selected drugs. All drugs in
the dataset are designed or used in respiratory indications,
cover a wide range of physicochemical properties and have
limited in vitro accumulation data reported in AMs. The se-
lected drugs and their respective physicochemical properties
are summarised in Table I, together with the location of the
drug target (intra- or extracellular). The corresponding chem-
ical structures are shown in the Supplementary Material
Figure S1. Drug uptake into AMs was investigated at a single
substrate concentration at 37°C and 4°C to determine the
dependence of cellular accumulation on active uptake and
passive diffusion processes, respectively. In addition, the accu-
mulation of a number of selected drugs in AMs was investi-
gated over a range of substrate concentrations. In order to
assess its contribution to uptake into AMs, lysosomal seques-
tration of the drugs was investigated in the presence of agents
that abolish lysosome-cytosol pH gradient; lysosomotropic
drug imipramine was included as a positive control in the
studies. Cell-to-medium concentration ratio (Kp) was deter-
mined in the presence and absence of these agents to evaluate
the extent of lysosomal accumulation. The in vitro data were
supported by staining of the cells with LTR under control
Table I Physicochemical Properties of 10 Drugs Selected for the Investigation of Drug Uptake and Lysosomal Sequestration in NR8383 Cell Line
Drug Target LogP LogD7.4 pKa_a pKa_b PSA (Å
2) a Acid–base Property References
Clarithromycin c Intracellular bacteria 3.16 1.57 – 8.99 183 Base (21)
Imipramine Extracellular serotonin receptor 4.80 2.38 – 9.50 6.50 Base (22–24)
Formoterol d, e Extracellular β2-receptor 1.99
a 2.60 10.1, 11.8 a 8.14 a 90.8 Base (25)
Fenoterol d Extracellular β2-receptor 1.09
a 0.74 9.40, 10.1 a 8.25 a 93.0 Base (25)
Terbutaline d Extracellular β2-receptor 0.90 −1.50
b 8.60, 11.0 9.90 72.7 Base (26–28)
Budesonide d Extracellular glucocorticoid receptor 2.47 a 2.47 a n/a 93.1 Neutral
Tiotropium bromide d Extracellular muscarinic receptor −1.23 a −1.49 a n/a 59.1 Permanently cationic
Ipratropium bromide d Extracellular muscarinic receptor −1.20 a −1.75 a n/a 46.5 Permanently cationic
Rifampicin c Intracellular bacteria 2.54 a 0.3 1.7 6.70 217 Zwitterion (29,30)
Ciprofloxacin c Intracellular bacteria 0.28 −1.11 6.30 8.60 74.6 Zwitterion (24,26)
pKa_a: acidic pKa; pKa_b: basic pKa; Physicochemical data were expressed as experimental values where available except indicated:
a Predicted using ADMET
PredictorTM v7.0; b Average value of two studies (27,28); Respiratory indications are c intracellular infections and d COPD and asthma; e Predicted LogP is
expected to be higher than indicated, as the measured LogD7.4 is higher than this value
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conditions and in the presence of a number of basic drugs and
the above mentioned chemical agents. Recommendations of
the application of NR8383 for the assessment of accumulation
and lysosomal sequestration of respiratory drugs are provided.
MATERIALS AND METHODS
Chemicals and Reagents
1-Aminobenzotriazole, ammonium chloride, ciprofoxacin,
clarithromycin, dimethyl sulphoxide, Imipramine, lactate de-
hydrogenase activity assay kit, monensin sodium salt, nigericin
sodium salt, trypan blue 0.4% and verapamil hydrochloride
were all from Sigma Aldrich Ltd., Dorset, UK. Budesonide,
ipratropium bromide, fenoterol, formoterol, terbutaline and
tiotropium bromide were all supplied by GlaxoSmithKline,
UK. Chloroform and formaldehyde 37–41% were from
Fisher Scientific, Loughborough, UK. Further chemicals in-
clude diazepam (Tocris Bioscience, Bristol, UK), methanol
(VWR, UK), midazolam (Hoffman La Roche, Switzerland),
Pierce BCA protein assay kit (Thermo Scientific,
Loughborough, UK) and Lysotracker® Red DND-99 (Life
Technologies, Paisley, UK). Reagents include bovine serum
albumin and penicillin-streptomycin (Sigma Aldrich Ltd.,
Dorset, UK), collagen Type I rat tail (BD Biosciences,
Oxford, UK), Dulbecco’s phosphate buffered saline and
heat-inactivated foetal bovine serum (Life Techonolgies,
Paisley, UK) and Kaighn’s modification of Ham’s F12
(Ham’s F12K) medium (American Tissue Culture Collection
(ATCC), Mannasas, VA, USA).
NR8383 Cell Culture and Maintenance
The NR8383 cell line (CRL-2192) was purchased from
ATCC, Mannasas, VA, USA. Cells were grown in Ham’s
F12K medium with 2 mM glutamine and 1.5 g/L sodium
bicarbonate which was further supplemented with 15%
heat-inactivated foetal bovine serum and 100 units/mL pen-
icillin-100 μg/mL streptomycin to make complete growthme-
dium (CGM). Cells, which were present as both floating and
attached cell populations, were routinely maintained in tissue
culture flasks. CGMwas changed twice per week and involved
removal of the floating cells from flasks, rapid addition of fresh
CGM into the flasks to maintain adherent cells in medium
and re-suspension of floating cells in CGM to be returned into
flasks. The latter was performed following centrifugation of
the cells at 142 g for 5 min (Eppendorf Centrifuge 5804,
Cambridge, UK) at room temperature. Upon ~70%
confluency was reached, cells were passaged by gentle scrap-
ing of the loosely attached cells into the existing culture medi-
um. Following centrifugation at aforementioned conditions,
cell pellet was gently re-suspended in 1 mL of CGM
previously maintained at 37°C and seeded into new flasks at
2×105 or 3.5×105 cells per mL. Cell count and viability were
assessed with trypan blue exclusion method using a
haemocytometer under the light microscope (Olympus
CK2, Olympus Optical Co., Japan). Cells were maintained
by incubation at 37°C, 5% CO2 in a humidified atmosphere.
Only cells with passage number up to 25 were used to ensure
consistency in the cell line morphology.
Drug Uptake in NR8383
The cellular uptake method was adapted fromMénochet et al.
(2012) (31) and optimised for NR8383, as outlined herein.
The studies were carried out in a 24-well plate format and
the in vitro conditions were optimised in terms of cell detach-
ment method from culture flasks, coating type of 24-well
plates, seeding density, culturing time and drug incubation
time points. Briefly, for cell detachment, gentle scraping versus
Mg2+-Ca2+ free DPBS treatment of cells in culture flasks were
tested. Considering the semi-adherent nature of AMs, cell
seeding into non-coated, collagen-I and poly-D-lysine coated
24-well plates was investigated for cell attachment, distribu-
tion in the wells and detachment following DPBS washes dur-
ing the uptake experiments. In addition, seeding densities of
0.36 and 0.72×106 cells per well were assessed with respect to
cell attachment, confluency following culture (plating efficien-
cy) and potential cell detachment following DPBS washes.
Culturing time ranging from 4 to 24 h was investigated for
optimal cell attachment before carrying out uptake experi-
ments. Uptake rate andKp data were normalised by cell num-
ber determined indirectly bymeasuring the amount of protein
in samples by bicinchoninic acid (BCA) protein assay (Thermo
Scientific, Loughborough, UK). Following the optimisation,
detachment of NR8383 from cell culture flasks was performed
by gentle scraping prior to cell counting and seeding into
collagen-I coated 24-well plates at 0.5×106 cells per well.
Cells were cultured for 16 h at 37°C, 5% CO2 (CO2 incuba-
tor, MCO-17AIC, Sanyo Biomedical, Loughborough, UK)
before uptake studies performed over 1 to 10 min period.
The details of method optimisation outlined above can be
found in the Supplementary Material, Figure S2.
Initially, uptake experiments in NR8383 were carried out
for all drugs at single substrate concentration of 5 μM at 37
and 4°C in order to delineate contribution of active uptake
and passive diffusion processes. The drug uptake in NR8383
corresponding to these conditions was described by total up-
take (CLuptake) and passive diffusion (CLdiff) clearance terms,
respectively. For a subset of selected drugs, accumulation was
assessed over a range of drug concentrations (0.1–100 μM for
imipramine, 1–100 μM for formoterol and clarithromycin) at
37°C. In addition, clarithromycin uptake kinetics was evalu-
ated over this concentration range. Substrate solutions were
prepared by dilution of the stock solutions in DPBS resulting
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in final DMSO content<1%. Uptake studies were performed
in the presence of 1 mMABT, a nonspecific P450 inhibitor, in
order to avoid any potential impact of phase I metabolism.
Currently there is no evidence of the presence of any conju-
gation enzymes in this cell line. Following microscopy, the
CGM was removed, cells were washed twice with 800 μL of
either pre-warmed or ice-cold DPBS (for experiments at 37
and 4°C, respectively) and pre-incubation with 500 μL of pre-
warmed or ice-cold ABT/DPBS was carried out for 20 min.
Where ABT pre-treatment was not necessary, cell monolayers
were treated with 500 μL of DPBS only. Once pre-incubation
buffer was removed from the cell monolayers, incubations
were started by addition of 400 μL of substrate solution (pre-
warmed or ice-cold) in each well. Each substrate was incubat-
ed with the cells for 1, 2, 5 and 10 min and each time point at
37°C and 4°C. For 37°C experiments, incubation was carried
out on a dry heater block maintained at 37°C throughout the
experiment (Tecam Dri-block DB-3, Tecam, Princeton, NJ)
and for 4°C experiments, the procedure was carried out on
ice. Incubation with substrate was stopped by removal of the
media with drug solution and washing the monolayers three
times with 800 μL ice-cold DPBS. The back-diffusion of the
drug from the cell into the medium was considered to be
negligible under these conditions. The removed incubation
media were retained for the measurement of drug medium
concentrations and subsequent determination of Kp for each
drug. The cells were lysed by addition of 200 μL ice-cold
deionised water; cell lysates were kept at −20°C overnight
and then processed further for LC-MS/MS analysis.
Experiments were performed on three or more separate oc-
casions for each drug investigated. Clarithromycin uptake at
5 μM was used as a control to assess the performance of
individual experiment. The mean uptake of the 5 μM
clarithromycin across a large number of experiments per-
formed (n=59) was 5.50±2.96 μl/min/106 cells. The amount
of protein per well was measured using a BSA calibration
curve and absorbances read at 562 nm (S22 Boeco UV-
Visible Spectrophotometer, Hamburg, Germany).
Determination of cell number from measured protein was
reproducible across experiments (1×106 cells=0.25±
0.06 mg protein, n=66).
Assessment of Lysosomal Sequestration in NR8383
Cells with LysoTracker Red
Qualitative assessment of the localisation of lysosomes in
NR8383 and lysosomal targeting of drugs investigated was
made using LTR (Life Technologies, Paisley, UK). The pro-
tocol used for staining of the cells with LTR was adapted from
a previous study (32). Clear flat bottom Ibidi 8-well chamber
slides (Thistle Scientific, Glasgow, UK) were previously coated
with 50 μg/mL collagen-I solution (4.05 mg/mL Collagen
type I rat tail, BD Biosciences, Oxford, UK). NR8383 cells
(250,000 cells/well) were plated in the slides and cultured for
16 h to 70–80% confluency and to ensure attachment. Stock
solutions of NH4Cl, monensin and nigericin were prepared by
diluting them in serum-free Ham’s F12K medium resulting in
final incubation concentrations of 20 mM, 5 μM and 10 μM,
respectively. In addition, stock solutions of clarithromycin,
imipramine and formoterol were diluted in fresh serum-free
Ham’s F12K medium containing 1 mM ABT to achieve final
incubation concentrations of 5 μM. LysoTracker Red was
added into the solutions of the chemical agents and the drugs
to achieve a final concentration of 200 nM as used previously
(14). A control solution of LTR at the same concentration was
also prepared by dilution of the original DMSO stock in
serum-free Ham’s F12Kmedium. Upon reaching confluency,
cells were examined under the microscope (Olympus CK2,
OlympusOptical Co., Japan), the CGMwas removed and the
cells were pre-treated with 300 μL warm DPBS containing
1 mM ABT for 20 min at 37°C in the presence of 5% CO2
(CO2 incubator, MCO-17AIC, Sanyo Biomedical,
Loughborough, UK). Following this, the cells were treated
with 300 μL of serum-free Ham’s F12K medium containing
either LTR alone (control) or LTR with each of the chemical
agents or selected drugs for 1 h at 37°C in the CO2 incubator
and protected from light. Following the incubation, the cells
were washed three times with 300 μL ice-cold DPBS and
immediately fixed with 4% (v/v) formaldehyde in DPBS for
10 min at room temperature, protected from light. The cells
were then treated with 50mMNH4Cl in DPBS to quench the
residual formaldehyde fluorescence for 5 min at room tem-
perature. Three subsequent washes with ice-cold DPBS were
performed before visualisation of LTR with a confocal laser
scanning microscope (Zeiss LSM 510, Jena, Germany) using a
C-Apochromat 40×/1.2 NA (Numerical Aperture) water-
immersion objective and helium/neon laser (λexcitation
543 nm, λemmision 560 nm). Images were collected and proc-
essed using Combi LSM-FCS v.3.2 and LSM Image Browser
v4.2 software (Jena, Germany). Furthermore, Image J v1.47
software was used for the quantification of the fluorescence
intensity of LTR in absence or presence of chemical agents
and basic drugs (Image J, National Institutes for Health, US).
The corrected total cell fluorescence (CTCF) was calculated as
integrated density – (area of selected cell x mean fluorescence
of background reading) (33). The CTCF of treated cells was
compared to 100% control (LTR only).
Lysosomal Sequestration Studies in NR8383
The extent of accumulation of drugs in lysosomes was assessed
using the same uptake methodology, as described above in the
absence and presence of NH4Cl and ionophores, monensin
and nigericin. Preliminary investigation of imipramine and
clarithromycin uptake was performed across a range of
NH4Cl concentrations (10–50mM), based on previous studies
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in the literature (12–14,34). In addition, a range of incubation
conditions was explored, including pre-incubation and co-
incubation alone and combined together. Once the conditions
were optimised, further experiments were performed with
20 mM NH4Cl co-incubated with investigated drugs. The
details of this optimisation work can be found in the
Supplementary Material, Table S2 and Figure S3.
Following the initial assessment with NH4Cl, confirmation of
lysosomal sequestration for a number of selected drugs was
further carried out by co-incubation of 5 μM monensin or
10 μM nigericin with the selected drugs. The concentrations
of both ionophores used in this study were optimised based on
previous reports (13,14,34) and in house solubility observa-
tions. Stock solutions of NH4Cl, monensin and nigericin were
in deionised water, methanol and chloroform respectively. For
incubations with NH4Cl, all drugs were prepared at 5 and
20 μM concentrations, with the exception of ciprofloxacin
due to solubility issues at higher concentrations. In the case
of clarithromycin, its accumulation was further evaluated in
the presence and absence of NH4Cl over a wide substrate
concentration range. The incubation time points with
NH4Cl were up to 10 min based on the previous data on
the changes in lysosomal pHwith this agent reported inmouse
peritoneal macrophages (35). For incubations with monensin
and nigericin, all drugs were prepared at 5 μM concentration
and the incubations were carried out for 5 min (single time
point). Following the treatment of the cell monolayers with
drug alone or drug with the agents mentioned, incubations
were stopped by washing of the cells with ice-cold DPBS as
described above, followed by cell lysis in deionised water. All
incubations were carried out in duplicate and experiments
were performed for three separate occasions. The removed
incubation media were retained for the measurement of drug
concentrations and subsequent determination of Kp for each
compound. Analysis of samples in LC-MS/MS was per-
formed after cells were kept at −20°C overnight.
Cytotoxicity Assessment
Lactate dehydrogenase (LDH) assay kit (Sigma-Aldrich,
Dorset, UK) was used to measure the cytotoxicity of the chem-
ical agents used to assess the extent of lysosomal sequestration
relative to untreated cells. In addition, the cytotoxicity was
assessed at high drug concentrations (50 and 100 μM) in cases
where uptake was investigated over a substrate concentration
range. The viability of the untreated cells and the effect of the
individual drugs and chemical agents, as well as the effect of
their combined use were assessed. Therefore, four types of
samples were included in the analysis; namely, the incubation
medium consisting of DPBS alone (negative control), drug
alone (e.g., clarithromycin), chemical agents alone (e.g.,
NH4Cl), and chemical agent and drug combination (e.g.,
NH4Cl+clarithromycin). For the assessment of the individual
chemical agents, same concentrations were used as in the ly-
sosomal sequestration studies. The cytotoxicity in above sam-
ples was measured on three separate occasions. The LDH
activity of the experimental samples was compared against
the 100% activity of the LDH positive control included in
the assay kit. All samples and standards were run in duplicate
and absorbance values were measured using a plate reader
(Tecan Safire, A-5082, Reading, UK). Data acquisition was
performed using Magellan software (version 7.1, Tecan
Group Ltd., Austria).
Sample Preparation and LC-MS/MS Analysis
All cell lysates and media samples were thawed and quenched
with methanol containing internal standard. The internal
standard concentration was 1 μM for all drugs except for
budesonide and rifampicin for which 0.1 μM was used. For
cell lysate and media samples, equal volume of methanol/
internal standard mixture (200 μL) was used. Media samples
with substrate concentrations of 10 μM and above were dilut-
ed down to 2 μMwith DPBS before quenching with the same
volume of methanol/internal standard mixture (200 μL). This
initial dilution was performed to avoid saturation of ionisation
in LC-MS/MS at high concentrations. Samples were placed
at −20°C for at least an hour to precipitate the proteins,
followed by their centrifugation at 2500 rpm for 10 min
(Eppendorf Centrifuge 5804, Cambridge, UK). Ten or
20 μL of supernatant was analysed by LC-MS/MS as detailed
below.
Samples were analysed on a Waters Alliance 2795 HPLC
system coupled to a Micromass Quattro Ultima mass spec-
trometer (Waters, Watford, UK) using electrospray positive
ionisation mode. All compounds and their internal standards
were separated on Luna C18 column (3 μm, 50×4.6 mm)
(Phenomenex, Macclesfield, UK), except for fenoterol, terbu-
taline, ipratropium and tiotropium bromide which were sep-
arated on Luna Phenyl Hexyl column (3 μm, 50×4.6 mm)
(Phenomenex, Macclesflield, UK). The mobile phases used
were: Solvent A, 90% water, 10% methanol, and 0.05%
formic acid; Solvent B, 10% water, 90% methanol, and
0.05% formic acid; Solvent C, 90% water, 10% methanol,
and 1 mM ammonium acetate; and Solvent D, 10% water,
90% methanol, and 1 mM ammonium acetate. The gradient
of mobile phases varied for each drug. The flow rate through
HPLC was 1 mL/min, which was then split to 0.25 mL/min
before entry into the mass spectrometer. For the Waters
Ultima, the capillary voltage was 3.5 kV; desolvation and
source temperatures were 350 and 125°C, respectively;
desolvation gas and cone gas flow rates were 600 and
150 L/h, respectively. LC-MS/MS conditions for each indi-
vidual drug and their corresponding internal standards are
detailed in Supplementary Material, Table S3. A calibration
standard, containing the compound of investigation at a
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concentration range covering that of the experimental sam-
ples with an additional zero blank, was prepared in the same
matrix of the experimental samples and analysed twice (before
and after the experimental samples) during each run, in order
to confirm compound stability, consistent peak area for inter-
nal standard and any potential compound carry over.
Samples were quantified against the standard curve using
MassLynx v.4.1 (Waters Inc., Milford, MA). During analysis,
only standards which were measured within 30% of the nom-
inal concentration were included in the standard curve.
Determination of Uptake Clearance Parameters
The CLuptake and CLdiff were estimated at a single substrate
concentration for each drug from the 37 and 4°C data, re-
spectively. Uptake rate was determined from the slope of the
linear regression of the cell concentration vs. time plot. Total
uptake clearance was then estimated from the ratio of the
uptake rate against the substrate concentration. Both
CLuptake and CLdiff were determined for each drug on a min-
imum three separate occasions. Uptake clearance attributed
to the active process(es) was determined from the difference
between CLuptake and CLdiff for each drug (36).
Determination of Drug Accumulation
Accumulation of drugs in NR8383 was determined by calcu-
lating Kp of all drugs at 5 μM at 10 min. Kp was determined
by Eq. 1 as reported previously (36,37);
Kp ¼ CcellCmedium ð1Þ
where Ccell and Cmedium represent concentration of the drug
in the cell and medium, respectively. Both represent the mea-
surements made at the final incubation time point (10 min).
The Kp represents partition of the drug into total cell and
reflects intracellular binding, subcellular distribution and ac-
tive and passive uptake processes. Ccell was calculated by mul-
tiplying the measured lysate concentration with lysate volume
(200 μL) and dividing this amount by the cell volume
(1.04 μL/106 cells, CV=24%) and number of cells measured
per well. Cell volume was calculated by multiplying the re-
ported NR8383 volume of 4.2 μL/mg protein (38) with the
amount of protein measured experimentally (0.25±0.06 mg/
106 cells). While Kp was determined at a single substrate con-
centration for all the drugs investigated, the accumulation of 3
basic drugs including imipramine, clarithromycin and
formoterol was also characterised over a concentration range
at the same incubation time. The concentration dependence
of drug accumulation was investigated by fitting the two-site
binding model to the Kp and concentration data in GraFit
v6.0.6 software (Erithacus Software Limited, Horley, UK).
The model incorporates a saturable site and a linear function
for unsaturated binding as shown in Eq. 2;
Kp ¼ Kp;U1;max−Kp;U1;max⋅CmediumKU1 þ Cmedium þKp;min ð2Þ
where Kp,U1,max is maximum Kp for saturable uptake, Kp,min
is Kp for nonsaturable uptake and KU1 is apparent saturable
uptake equilibrium constant. Kp for maximum total uptake
was calculated as the sum of Kp,U1,max and Kp,min, as reported
previously (39).
Determination of Uptake Kinetic Parameters
of Clarithromycin
The estimation of uptake kinetic parameters of clarithromycin
was performed using the two-step method (31,36) for analysis
in GraFit v6.0.6 (Erithacus Software Limited, Horley, UK).
CLdiff was estimated from the slope of the linear regression of
the substrate concentration vs. uptake rates estimated at 4°C
and used as a constant parameter in Eq. 3. When estimating
the uptake kinetic parameters in the presence of NH4Cl,
CLdiff estimated at single substrate concentration was used a
constant in the equation. Subsequently, kinetic parameters
Km
′ and Vmax were obtained by nonlinear regression.
v ¼ Vmax  Smed
Km0 þ Smed þ CLdiff  Smed ð3Þ
where v is the uptake rate, Km
′ is the binding affinity constant
and Vmax is the maximum uptake rate associated with an
active process mediating uptake of clarothromycin into AM.
Smed (μM) is the nominal media concentration corrected for
fraction unbound in the media (fumed=0.93±0.03). The latter
was determined from the slope of the linear regression of the
unbound concentration extrapolated at time 0 vs. the nominal
incubation concentration plot.
Determination of Lysosomal Sequestration
Kp and CLuptake were determined as described above for each
drug both under control condition and in the presence of a
chemical agent affecting the pH gradient between cytosol and
lysosomes. The reduction in Kp and CLuptake of each drug in
the presence of the chemical agents was expressed as a per-
centage relative to control and used as an indicator of the
extent of lysosomal sequestration. A 50% reduction in both
parameters was set as a cut-off for lysosomal accumulation,
while also taking into account the physicochemical properties
of the compounds (Table I) and the uncertainty associated
with the experimental data.
The in vitro parameters were calculated on at least three
separate occasions and the mean data were reported. When
assessing the extent of lysosomal sequestration, the control and
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chemical agent treated cells were compared using the two-
tailed, paired t-test in order to determine statistically signifi-
cant difference between the two conditions. Values were re-
ported as significant when p<0.05.
RESULTS
Drug Accumulation in NR8383 Cell Line
Accumulation of 10 drugs was assessed in NR8383 at a single
substrate concentration (5 μM) at 37°C. Measured cell and
media concentrations of all drugs were used to determine their
Kp, as shown in Table II. More than 500-fold range in Kp was
observed in NR8383 for the current dataset. The most exten-
sive accumulation in NR8383 was seen for imipramine and
clarithromycin (Kp of 391 and 82, respectively) .
Ciprofloxacin, rifampicin, budesonide and formoterol accu-
mulated in NR8383 to a similar extent (Kp values ranging
between 25 and 43). For the remaining drugs, relatively less
partitioning into cells was observed, as tiotropium,
ipratropium bromide and fenoterol achieved a Kp between
5 and 9. In the case of terbutaline, the medium concentration
of the compound remained higher than its cell concentration
throughout the incubation period, resulting in Kp close to 1.
For a number of basic drugs, accumulation in the NR8383
was assessed further over a range of substrate concentrations.
A concentration-dependent accumulation was observed for
the drugs investigated, as illustrated in Fig. 1. The two-site
binding model was fitted to the experimental data and the
estimated uptake parameters Kp,U1,max, Kp,min and KU1 are
shown in Table III. In contrast to the Kp value obtained at
5 μM, imipraminemaximumKp of 1166was estimated by the
modelling approach (corresponds to concentration <0.1 μM).
The Kp,min of 141, 24 and 10 was estimated for imipramine,
clarithromycin and formoterol, respectively. The analysis
indicated that half of maximal Kp associated with saturable
uptake would be reached at concentrations below 2 μM for
these three drugs (Table III). The fold difference between Kp,
max andKp,min ranged between 3 and 8 for clarithromycin and
imipramine, respectively.
Uptake of 10 drugs was also assessed in NR8383 at 5 μMat
37 and 4°C in order to delineate contribution of active and
passive diffusion processes to the overall uptake into AMs
(Table II). The trends seen in the intracellular accumulation
data were reflected in the uptake clearances, with over 400-
fold range in CLuptake in NR8383 observed for the current
dataset (0.04–16.7 μL/min/106 cells). Imipramine showed
the highest uptake clearance in NR8383 (16.7 μL/min/106
cells) with maximal contribution of the passive process to the
total uptake of approximately 30%. Negligible CLdiff was ob-
served for clarithromycin, suggesting a large contribution of
an active process to its accumulation in NR8383. The same
trend was observed for the majority of drugs with the excep-
tion of terbutaline and budesonide where contribution of pas-
sive diffusion to accumulation in NR8383 was >50%
(Table II). Fenoterol, terbutaline, ipratropium and tiotropium
bromide were marginally taken up into NR8383 cells with a
CLuptake of<1 μL/min/10
6 cells.
Confocal Microscopic Examination of NR8383 Cells
and Lysosomal Sequestration
The imaging of NR8383 cells was performed in order to con-
firm localisation of functional lysosomes in NR8383 and assess
the effect of the chemical agents on LTR accumulation in
these organelles. In addition, the lysosomal targeting of select-
ed drugs was investigated. A differential contrast image was
taken every time prior to excitation of the cells for LTR de-
tection. A representative of this image is shown in Fig. 2a,
demonstrating the presence of cytoplasmic vesicular structures
likely to represent acidic organelles including lysosomes. The
Table II Drug Uptake Clearance and Cell-to-Medium Concentration Ratio (Kp) of 10 Drugs in NR8383 at 5 μM Substrate Concentration. Data Represent








Imipramine 16.7±4.3 5.06±1.7 30.2 391±108
Clarithromycin 6.0±3.7 0.03±0.03 0.53 81.6±22.8
Formoterol 2.0±0.7 0.08±0.08 3.71 24.5±8.71
Budesonide 1.5±0.7 1.5±0.9 97.2 37.6±11.4
Rifampicin 1.4±0.5 0.03±0.01 1.87 38.6±18.1
Ciprofloxacin 1.3±0.4 0.3±0.2 22.3 43.0±21.1
Tiotropium bromide 0.4±0.3 0.06±0.04 16.3 8.74±7.24
Fenoterol 0.3±0.2 0.03±0.01 8.03 5.69±0.98
Ipratropium bromide 0.2±0.2 0.01±0.01 5.19 5.42±3.38
Terbutaline 0.04±0.01 0.02±0.01 47.6 0.69±0.16
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corresponding fluorescent image of the same cell is illustrated
in Fig. 2b where LTR was localised in lysosomes, confirming
the presence of these organelles in NR8383 cells. Treatment
of NR8383 with LTR in the presence of NH4Cl (20 mM),
monensin (5 μM) and nigericin (10 μM) showed reduced fluo-
rescent signal up to 85% for all agents. The reduced accumu-
lation of LTR in the presence of these agents (Fig. 2c, e, g)
confirmed lysosomal targeting of this basic probe in NR8383.
Assuming the competition of basic drugs for lysosomal seques-
tration, LTR was co-incubated with 5 μM of clarithromycin,
imipramine and formoterol. Clarithromycin and imipramine
decreased LTR accumulation by 86 and 72%, respectively
(Fig. 2d, f), confirming indirectly the lysosomotropic properties
of these two drugs. In contrast, the localisation of LTRwas still
evident in the presence of formoterol (Fig. 2h) which caused
only 25% reduction in LTR accumulation, suggesting its mar-
ginal targeting of NR8383 lysosomes.
Cytotoxicity Assessment
Analysis of all three agents either on their own or when co-
incubated with clarithromycin or imipramine showed mini-
mal cytotoxicity (less than 2% compared to 100% positive
control). At all times, the viability of the control (i.e., untreated)
cells was more than 95%. The measured cytotoxicity was less
than 1% for imipramine at both 50 and 100 μM
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Fig. 1 Cell-to-medium concentration ratio (Kp) of imipramine (a), formoterol (b) and clarithromycin (c), and total uptake rate of clarithromycin (d) over a range
of concentrations in NR8383 cells. Data represent mean±SD of 3 experiments except for the first two data points (0.1–0.5 μM) of imipramine (n=1). Solid line
represents the fit for total uptake at 37°C. Symbols represent the observed data in the absence ( imipramine; formoterol; clarithromycin) and presence ( )
of 20 mMNH4Cl at 37°C. For Kp and uptake kinetic parameter estimation, the fitting was obtained using the two-site binding model (Eq. 2) and the conventional
two-step model (Eq. 3).
Table III Uptake Parameter Values for 3 Drugs Investigated in NR8383 Over a Concentration Range. Kp,U1,max, Kp,min and KU1 were Estimated Using the
Two-Site Binding Model. Data Represent Mean±SD of 3 Experiments
Drug Kp,U1,max Kp,min KU1 (μM) Kp,max Kp,max/Kp,min
Imipramine 1025±99.6 141±30.6 0.9±0.3 1166 8.3
Clarithromycin 44.9±16.6 24.2±2.06 1.18±1.45 69 2.9
Formoterol 59.2±8.77 10.0±0.92 1.54±0.49 69 6.9
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concentrations. For formoterol, the cytotoxicity was less than
5% compared to the positive control, whereas in the case of
clarithromycin, the cytotoxicity levels were <3% and 10% for
50 μM and 100 μM concentrations, respectively.
Assessment of Lysosomal Sequestration in NR8383
Lysosomal sequestration of 10 drugs was assessed in NR8383
cells using three different chemical agents. The analysis was
performed initially with 20 mM NH4Cl co-incubated with
each drug at 37°C for 10 min. The pH of the incubation
medium showed a minimal reduction in the presence of
NH4Cl (<0.06 unit) relative to control conditions. The effect
of NH4Cl on the intracellular accumulation of individual
drugs is shown in Fig. 3. Of all the drugs investigated, the most
pronounced reduction in intracellular accumulation was ob-
served for clarithromycin, as Kp obtained at 5 μM decreased
by 6-fold in the presence of NH4Cl relative to control condi-
tion, whereas in the case of imipramine 3.4-fold lower Kp was
seen (Table IV). The presence of NH4Cl in the incubation did
not significantly alter the intracellular accumulation of the
remaining drugs (Table IV and Supplementary Material,
Table S4). Even though Kp was reduced for some of the drugs
(e.g., by 46% for ipratropium bromide), the large uncertainty
associated with the data (both control and+NH4Cl data) re-
sulted in no significant difference between the two conditions.
For the majority of drugs, the% reduction in Kp in the pres-
ence of NH4Cl was within 20% at both substrate
concentrations.
Lysosomal sequestration of imipramine, clarithromycin,
formoterol and fenoterol was investigated further by
monensin and nigericin; total Kp of these drugs in the absence
and presence of these agents are shown in Fig. 4. The Kp of
imipramine was significantly reduced in the presence of both
monensin (by 66%) and nigericin (by 75%). The reduction of
clarithromycin Kp was more pronounced in comparison to
imipramine (77 and 82% by monensin and nigericin, respec-
tively), in agreement with the effect of NH4Cl. In contrast,
minor reduction in fenoterol and formoterol Kp in the pres-
ence of these agents was observed, corroborating findings
from the studies with NH4Cl. The observations from confocal
imaging studies confirmed the results outlined above, with
regards to both the effectiveness of the chemical agents and
the extent of lysosomal accumulation of clarithromycin, imip-
ramine and formoterol (Fig. 2). In addition to Kp, CLuptake of
each drug was estimated in the presence of these chemical
agents; the effect of NH4Cl, monensin and nigericin on
CLuptake of the drugs investigated followed the same trends
seen for Kp data (details are shown in the Supplementary
Material, Table S5, Figures S4 and S5).
Among all drugs, the accumulation of clarithromycin in
NR8383 in the presence of NH4Cl was further characterised
over a range of clarithromycin concentrations (1–100 μM).
Compared to control conditions, a marked reduction in
clarithromycin Kp was observed at all drug concentrations
(Fig. 1c). Estimated Kp,U1,max and Kp,min values in the pres-
ence of NH4Cl were 9.7 and 4.7, respectively, resulting in a
mean maximum fitted Kp of 14.4. Assessment of uptake ki-
netics of clarithromycin under the control conditions showed
a c e g
NR8383 + NH
4
Cl + Monensin + Nigericin
b d f h
+LysoTracker Red  + Clarithromycin            + Imipramine + Formoterol
(Control)
Fig. 2 Qualitative assessment of lysosomal sequestration of LysoTracker Red (LTR) and three drugs studied in NR8383 by confocal microscopy: (a) differential
interference contrast image of a single NR8383 cell treated with 200 nM LTR; (b) the same cell being excited to detect LTR localised in lysosomes under control
conditions; the localisation of LTR in the lysosomes of NR8383 was reduced in presence of 20 mMNH4Cl (c), 5 μMmonensin (d), 10 μM nigericin (e), 5 μM
clarithromycin (f) and 5 μM imipramine (g), and showed minor changes in presence of 5 μM formoterol (h).
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Table IV Cell-to-Medium Partition Coefficients (Kp) Estimated Under Control and NH4Cl Treatment Conditions for 10 Drugs Investigated at 5 μM in
NR8383. Percent Reduction in Kp in the Presence of NH4Cl (20 mM), monensin (5 μM) and nigericin (10 μM) is shown as an indicator of the extent of lysosomal
Sequestration. Data Represent Mean±SD of at Least 3 Experiments
% Reduction in Kp by
Drug Kp Control Kp + NH4Cl NH4Cl Monensin Nigericin
Imipramine 347±59.8 102±17.1 71±2.6** 75±11** 66±11**
Clarithromycin 82.7±27.3 13.3±6.50 84±6.6** 77±8.5** 82±9.6**
Formoterol 20.8±3.6 15.5±1.16 24±9.0 40±7.5 27±5.1*
Fenoterol 4.25±2.64 2.91±2.11 31±23 27±25 30±12
Terbutaline 0.92±0.39 0.72±0.31 21±5.0 n/a n/a
Rifampicin 27.9±3.54 33.2±11.9 NR n/a n/a
Tiotropium bromide 4.39±2.90 3.87±2.61 12±1.8 n/a n/a
Ipratropium bromide 4.94±0.30 2.69±1.09 46±21 n/a n/a
Budesonide 31.5±8.46 28.1±7.12 10±7.8 n/a n/a
Ciprofloxacin 43.0±21.1 37.6±20.5 15±13 n/a n/a
n/a not available, NR no reduction in Kp;
* , p<0.05; ** , p<0.01 by t-test
a
b
















Fig. 3 Kp (Ccell/Cmedium) estimated in absence ( ) (control) and presence ( ) of 20 mM ammonium chloride (NH4Cl) at 5 μM concentration of (a) imipramine,
clarithromycin, formoterol, rifampicin, budesonide, ciprofloxacin, and (b) ipratropium bromide, fenoterol, tiotropium bromide and terbutaline. Data represent
mean±SD of at least 3 experiments carried out at separate occasions (**, p<0.01 by t-test).
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nonsaturating conditions up to 100 μM and therefore, the
kinetic parameters could not be determined. In contrast, in
the presence of NH4Cl, the uptake rates of clarithromycin
were reduced markedly at all substrate concentrations com-
pared to the control condition (Fig. 1d) and showed a satura-
ble uptake kinetic profile (despite highly variable rates at
higher concentrations, CV>30%). In the presence of
NH4Cl, Km
′ and Vmax associated with the active uptake of
clarithromycin into NR8383 were 28.5 μM and 12.4 pmol/
min/106 cells, respectively; the corresponding clearance was
0.43 μL/min/106 cells. Considering estimated marginal con-
tribution of the passive process, total clarithromycin CLuptake
(0.46 μL/min/106 cells), was in agreement with the value
obtained at a single concentration in the presence of NH4Cl
(Supplementary Material, Figure S4).
DISCUSSION
Many clinically used drugs are basic and lipophilic, with a
high propensity to accumulate in lysosome rich tissues, includ-
ing the lungs. Depending on the location of intracellular drug
targets the consequence of lysosomal sequestration varies, and
could affect the efficacy of respiratory drugs targeting airway
submucosa l compartments ( e . g . , β2-agonis t s and
antimuscarinics). Drug accumulation in AMs may lead to for-
mation of foamy macrophages (e.g., in drug induced
phospholipidosis) and may raise safety concerns. Currently,
there is a paucity of in vitro studies investigating the accumula-
tion of respiratory drugs and potential lysosomal distribution
in either primary human AMs or macrophage cell lines. In the
current study, comprehensive analysis of uptake and lysosom-
al sequestration of 10 drugs was performed in NR8383. This
rat alveolar macrophage cell line was selected as a represen-
tative AM system due to its ease of culturing and reported
comparable characteristics to freshly isolated rat AMs (17,18).
Assessment of Drug Accumulation and Membrane
Partitioning in NR8383
Following the optimisation of the methodology, the uptake of
10 drugs was investigated in NR8383 at a single concentration
(5 μM) limited by the analytical quantification of the cellular
concentrations of the drugs investigated. The analysis showed
pronounced differences in the extent of accumulation illustrat-

















































Fig. 4 Kp (Ccell/Cmedium) estimated in NR8383 in the absence ( ) (control) and presence of (a) 10 μM nigericin ( ) (b) 5 μM monensin ( ) at 5 μM
concentration of imipramine, clarithromycin, formoterol and fenoterol. Data represent mean±SD of at least 3 experiments (**, p<0.01 by t-test).
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min/106 cells) and Kp (0.7–391) for the drugs in the dataset.
Imipramine and clarithromycin, as the two most lipophilic
basic drugs, showed the highest intracellular accumulation in
NR8383, in agreement with previous studies reporting accu-
mulation of clarithromycin and a number of CADs in AMs
in vitro (12,40–42). A number of studies also reported substan-
tial imipramine accumulation in isolated perfused lungs of rats
(estimated Kp of 17–44 depending on concentration), or other
cell systems including rat hepatocytes (Kp,max 360) (37,43,44).
Recently, clarithromycin Kp of ~16 was reported in NR8383;
the estimate is based on measurements at 10 min at 37°C and
is approximately 5-fold lower than the Kp obtained here (12).
This discrepancy can be explained by the use of much higher
initial clarithromycin concentration (50 μM) in the study by
Togami et al. (2013) (12) compared to the current analysis. For
the remaining respiratory drugs investigated, relatively lower
intracellular accumulation in AMs was observed (Table II)
reflective of their physicochemical properties. Most drugs
have limited plasma membrane permeability due to being
largely ionised and relatively hydrophilic at physiological
pH, and are non-amphiphilic in structure, supporting no ex-
tensive partitioning into membranes (Table I).
In this present study, the mechanisms driving the uptake of
respiratory drugs in AMs were investigated at both 37 and 4°C.
Although the reliability of the 4°C approach to accurately de-
termine passive diffusion is often questioned because of the re-
duced fluidity of the cellular membrane (45), this method was
used as the presence of any membrane transporters in NR8383
is currently unknown, hence eliminating the possibility to assess
the process by the use of specific transporter inhibitors. Uptake
of most drugs into NR8383 was driven by an active process,
reflected in <25% contribution of the passive diffusion to the
total uptake for 7/10 drugs investigated. The largest contribu-
tion of active uptake process(es) to overall intracellular accumu-
lation in NR8383 was observed for clarithromycin. This finding
is in agreement with Togami et al. study (12) that showed a
reduction in clarithromycin Kp by 90% in NR8383 at 4°C
compared to its value at 37°C. In the case of rifampicin,
formoterol, ipratropium and tiotropium bromide, the
supporting evidence for their active uptake comes from other
systems such as HEK293 cells, Xenopus laevis oocytes and hu-
man airway epithelial cells in which the involvement of OATP,
OCT and OCTN transporters was highlighted (46–51).
In addition to the analysis at a single drug concentration, the
accumulation of imipramine, clarithromycin and formoterol (all
basic drugs) in NR8383 was characterised further by determin-
ing Kp over a range of substrate concentrations. The accumu-
lation of these drugs was concentration-dependent and best de-
scribed by a two-site model consisting of a saturable process,
attributed to either transporter-mediated uptake and/or lyso-
somal sequestration, and a second linear process representing
nonsaturable binding to membrane acidic phospholipids
(22,37,39). The two-site binding model allowed determination
of the maximal extent of accumulation (Kp,max) of investigated
drugs in AMs which can be difficult to assess analytically, as it
requires use of very low substrate concentrations. The extent of
saturable uptake was approximately 3-fold for clarithromycin,
whereas the magnitude of this uptake was much greater for
formoterol and imipramine (Kp,max/Kp,min ratio of 6.9 and
8.3, respectively). The accumulation profile of imipramine in
NR8383 is in agreement with the study by Hallifax and
Houston (37) who also described its accumulation in rat hepa-
tocytes as a two-site process including a high affinity-low capac-
ity component (saturable) and a low affinity-high capacity pro-
cess (nonsaturable). Similar concept was also previously pro-
posed for imipramine accumulation in lysosomes isolated from
rat liver (52), where the high affinity-low capacity site was attrib-
uted to lysosomes considering the effect of NH4Cl seen. Based
on these, the Kp,min of the drugs at the highest substrate concen-
tration can be assumed to represent membrane partitioning
upon saturation of active processes. Imipramine, as a CAD well
known to interact with membrane acidic phospholipids (53,54),
showed the highest membrane partitioning (Kp,min of 141)
whereas in the case of clarithromycin and formoterol Kp,min
values were 5 to 14-fold lower (Table III). This less pro-
nounced partitioning into membranes (lysosomal and cel-
lular plasma membrane) is not surprising considering the
non-amphiphilic and relatively less lipophilic nature of
clarithromycin and formoterol relative to imipramine.
Assessment of Lysosomal Sequestration of Drugs
in NR8383
Lysosomal sequestration is an important active process that may
contribute to intracellular drug accumulation. The qualitative
assessment of this process was performed with LTR staining of
NR8383 in the absence and presence of NH4Cl, monensin and
nigericin, agents known to abolish lysosome-cytosol pH gradi-
ent. In the quantitative analysis, the reduction in total drug
uptake clearance and accumulation by the mentioned chemical
agents was assessed. This indirect method provides an advan-
tage over methods requiring cell homogenisation and differen-
tial centrifugation to isolate lysosomes, as it is simple, rapid and
allows a larger number of compounds to be assessed. In addi-
tion, it avoids issues of poor recovery, potential contamination of
lysosomes and drug diffusion from these organelles during sam-
ple preparation. The extent of reduction in intracellular accu-
mulation of investigated drugs in NR8383 obtained in the pres-
ence of chemical agents differed substantially for the drugs in the
dataset. No or minimal reduction in Kp (<15%) was observed
for zwitterions rifampicin and ciprofloxacin, neutral budesonide
and permanently cationic tiotropium bromide. Among basic
drugs, the reduction in Kp was in the range of 20–40% for
formoterol, fenoterol and terbutaline. Out of all drugs, signifi-
cant lysosomal accumulation in NR8383 was observed only for
basic imipramine and clarithromycin (reduction in Kp of 65%
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and above). In the case of imipramine, the results were in agree-
ment with the use of this drug as a prototypical CAD for the
assessment of lysosomal sequestration, as demonstrated in nu-
merous different in vitro systems either in the presence of the
chemical agents (Supplementary Material, Table S1) or LTR
(14,55). Although clarithromycin is cationic, it is not an amphi-
philic drug due to the absence of the typical hydrophobicmoiety
(an aromatic and/or aliphatic ring structure) present in many
CADs (56). However, macrolides have been indicated to be one
of the few exceptions which lack the typical CAD structure yet
cause phospholipidosis linked to lysosomal sequestration (5).
Lysosomal accumulation of clarithromycin was observed for
the first time across a concentration range, supported by the
reduction in its Kp in the presence of NH4Cl at all drug con-
centrations including 100 μM. These findings suggest that even
at high concentrations, its intracellular accumulation was not
driven solely by membrane partitioning but also by the
lysosome-cytosol pH gradient. Therefore, the true membrane
partitioning (i.e., Kp,min) of clarithromycin is likely to be closer to
the estimate obtained in the presence of NH4Cl. No such data
currently exist in the literature to allow direct comparison.
Togami and colleagues previously showed that treatment of
NR8383 with NH4Cl reduced the amount of clarithromycin
in the cells by approximately half and the fraction of the drug
in the granules compartment (containing the lysosomes) by 75%
(12), in excellent agreement with the reduction in Kp obtained
in the current study.
The inclusion of basic drugs in this study was driven by
their basic pKa (range from 8.14 to 9.9), which together with
the lysosome-cytosol pH gradient suggested potential accumu-
lation in the lysosomes (predicted Kp,lysosome based on pH
partitioning ranged between 315 and 443 for terbutaline
and imipramine, respectively). However, under the experi-
mental conditions used herein, 3 out of 5 basic drugs with
LogP<3 failed to show substantial lysosomal accumulation,
suggesting that both sufficient lipophilicity and ionisation are
required for lysosomal accumulation within relatively short
incubation times. This finding was in agreement with a num-
ber of studies reporting lysosomal sequestration for drugs with
LogP>2 and pKa between 6.5 and 11 (14,55). However, it is
also evident that the mentioned physicochemical space is not
definitive and that a number of drugs with these properties
may fail to accumulate in the lysosomes. The discrepancy may
be explained by the previous reports showing that drugs with
similar octanol-water partition coefficients in unionised and
ionised forms did not accumulate in the lysosomes to the same
extent (mitochondrial accumulation was observed in-
stead). This finding was in contrast to drugs for which
partition coefficients of the ionised form were much
lower relative to neutral (all have the above mentioned
physicochemical properties) (15).
An important finding of the current lysosomal sequestra-
tion studies was the altered accumulation kinetics of
clarithromycin in NR8383 when its lysosomal sequestration
was significantly reduced in the presence of NH4Cl. While it
was not possible to determine the uptake kinetic parameters
for clarithromycin under control incubation conditions, the
initial uptake rates were substantially reduced in the presence
of NH4Cl and the kinetic parameter estimates could be ob-
tained. It is uncertain whether these estimates truly reflect the
existence of a membrane transporter in NR8383 and further
investigation of transporters expressed in this cell line is re-
quired. The existing evidence for clarithromycin being a sub-
strate for membrane transporters is conflicting. Although it
was previously shown that it was subject to active hepatic
uptake (36), a more recent study demonstrated that
clarithromycin was not a substrate for OATPs and OCT1
in vitro (transfected HEK293 cells) and in vivo in OATP and
OAT gene knockout mice (57). One potential explanation for
the more saturable kinetics under NH4Cl condition is the
saturation of lysosomal accumulation with increasing
clarithromycin concentration. These results further suggest
that for CADs, macrolides and other basic lipophilic drugs
which accumulate in the lysosomes, the uptake kinetic param-
eter estimates obtained may not represent the true transporter
affinities and uptake rates without adequate consideration of
the lysosomal sequestration. This is particularly important if
in vitro generated uptake kinetic parameters are to be used in
physiologically-based pharmacokinetic models to predict
in vivo transporter-mediated disposition of these drugs
(58–61). Considering many lysosomotropic drugs are cationic
and amphiphilic, these results warrant the need for studies to
investigate the impact of lysosomal sequestration on uptake
kinetics of known OCT and OCTN substrates.
In conclusion, the current study is the first to provide a
comprehensive analysis of the extent of accumulation of a
range of respiratory drugs in alveolar macrophages and the
mechanisms contributing to the observed intracellular drug
concentrations. The current data suggest minimal sequestra-
tion of inhaled drugs in lysosomes of alveolar macrophages;
however, formulation and particle size also need to be taken
into consideration in the translation of the findings to the in vivo
setting. The study has highlighted the importance of both
lysosomal sequestration and binding to acidic phospholipids
for extensive cellular accumulation in AMs, which are distinct
to transporter-mediated cellular uptake. Clarithromycin ex-
ample clearly emphasizes the relevance of lysosomal seques-
tration on the understanding of the cellular accumulation ki-
netics and interplay with other active processes affecting intra-
cellular drug concentrations. The abundance of lysosomes in
NR8383, together with the data presented here, indicate po-
tential application of this cell line in preclinical drug develop-
ment as a routine system for investigation of lysosomal seques-
tration of new drug candidates. In addition, NR8383 may be
used to predict the extent of respiratory drug accumulation in
human AMs and to validate mechanistic in silico models
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developed to predict subcellular drug distribution. Therefore,
this study provides a considerable scope for future research in
the area of the prediction of respiratory drug accumulation in
human alveolar macrophages.
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